

- Immune response/immune system, **372e-1**.  
*See also* Cell-mediated immunity  
 adaptive. *See* Adaptive immune system  
 aging and, 94e-4  
 antitumor effects, 103e-20  
 in celiac disease, 1940–1941  
 cellular interactions in regulation of, 372e-22–23  
 cellular migration in, 372e-28f  
 clinical evaluation of, 372e-30  
 components of, 2103  
 endogenous derangements of, 377e-2. *See also* Autoimmunity  
 endothelium in, 265e-2  
 exogenous derangements of, 377e-1–2  
 of gut, dysfunction of, 1876  
 gut microbiota and, 86e-8  
 in HIV infection. *See* HIV infection, immune response to  
 in IBD, 1949–1950  
 innate. *See* Innate immune system  
 laboratory evaluation of, 2757–2764t  
 molecular defects of, 372e-27t  
 at mucosal surfaces, 372e-23, 372e-25f  
 pattern recognition in. *See* Pattern recognition receptors (PRRs)  
 suppression by cancer cells, 102e-17–18, 102e-18f  
 terminology related to, 372e-1–2  
 in women, 6e-4
- Immune thrombocytopenic purpura, 413, 728–729
- Immune tolerance, 372e-23, 735
- Immunization, **785**. *See also* Vaccine(s)  
 for adults, 29t, 786  
 administration of, 791–792, 791f  
 contraindications to, 786, 789–790t, 790  
 determining need for, 786  
 provider recommendation for, 792  
 schedules for, 786, 787–788f  
 system support for, 792–793  
 for cancer patient, 485t, 492  
 for children, 2021–2022, 2022t  
 consumer access to and demand for, 792  
 documentation of, 792  
 for health care workers, 793, 918  
 in HIV infection, 788f, 798  
 in HSCT recipients, 139e-4  
 in nonmedical settings, 793  
 performance monitoring, 793  
 in pregnancy, 50–51, 788f, 790  
 for transplant recipient, 928–929, 929t  
 for travelers, 794–796, 795t
- Immunoblastic lymphomas, 1270. *See also* Diffuse large B-cell lymphoma
- Immunochemiluminometric assays (ICMAs), 2288
- Immunocompromised patient. *See also* Transplant recipient  
 abdominal pain in, 105  
 actinomyces in, 1091  
 adenovirus infection in, 1208  
 antibacterial therapy in, 936  
 bite-wound infection in, 167e-1  
*Candida* infections in, 350  
 CMV infections in, 1191t, 1192  
 diarrhea in, 266, 270, 855  
 HRSV infection in, 1205  
 immunization in, 788f, 790  
 primary CNS lymphoma in, 601–602  
 rhinovirus infection in, 1203  
 sexual practices of, 492  
 sinusitis in, 226  
 skin cancer in, 388
- Immunodeficiency viruses, 1216, 1216f, 1219–1220. *See also* HIV
- Immunodeficiency with centromere instability and facial anomalies (ICF), 375e-2, 2109
- Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), 377e-2, 2113, 2347–2348
- Immunofluorescent antibody technique, 150e-2
- Immunoglobulin(s). *See also* Antibody(ies)  
 in adaptive immunity, 372e-21–22  
 classification of, 710  
 electrophoresis of, 710–712, 712f  
 gene rearrangements in, 372e-20–21, 710, 711f  
 hyperimmune, for viral hemorrhagic fever, 261e-5t  
 properties of, 372e-21t  
 reference values for, 2761t  
 replacement of, 2112  
 structure of, 372e-20f, 372e-21, 710, 711f  
 types of, 372e-15
- Immunoglobulin A (IgA), 372e-21t, 372e-22, 372e-25t
- Immunoglobulin A (IgA) deficiency, 2111–2112
- Immunoglobulin A (IgA) nephropathy. *See* IgA nephropathy
- Immunoglobulin D (IgD), 372e-21t, 372e-22
- Immunoglobulin E (IgE)  
 allergies and, 1670  
 antibody to, 1678, 2119  
 assays for, 2122  
 in asthma, 1672  
 in atopic dermatitis, 344  
 properties of, 372e-21t
- Immunoglobulin E (IgE) receptor, 372e-24t
- Immunoglobulin G (IgG), 138e-1, 2112  
 properties of, 372e-21t, 372e-22  
 receptors for, 372e-7  
 in rubella, 230e-2
- Immunoglobulin M (IgM)  
 in *Brucella* infections, 194e-3  
 production of, 138e-1  
 properties of, 372e-21t  
 in rubella, 230e-2
- Immunoglobulin replacement, 492, 2112
- Immunologic memory, 372e-16
- Immunologic priming, 372e-16
- Immunologic synapse, 372e-19
- Immunomodulators, transfusion-related, 138e-6
- Immunoproliferative small intestinal disease, 537, 719
- Immunoreceptor tyrosine-based activation motifs (ITAMs), 372e-19, 2115
- Immunosuppression  
 in burn patients, 166e-2  
 by cancer cells, 102e-17–18, 102e-18f  
 UV-induced, 388
- Immunosuppressive therapy  
 after cardiac transplantation, 1517  
 after kidney transplantation, 1828–1829, 1829t  
 after liver transplantation, 2070–2071  
 chronic meningitis associated with, 911  
 immunization during, 790  
 for myasthenia gravis, 2705  
 osteoporosis associated with, 2492
- Immunotherapy  
 for allergic rhinitis, 2122–2124, 2123f  
 for asthma, 1678  
 for autoimmune and inflammatory diseases, 372e-30–31  
 for cancer, 102e-17–18  
 contraindications to, 2124
- Immunotoxicity, 91e-2t
- Impaired physician, 17e-4
- Impella device, 296e-5
- Impetigo, **349**  
 bullous, 349, 361t, 362, 829, 967  
 burn-wound, 166e-1  
 clinical features of, 341t, 349, 350t, 967, 967f  
 differential diagnosis of, 967  
 etiology of, 349, 350t, 966–967  
*S. aureus*, 349, 350t, 967  
 streptococcal, 966–967  
 treatment of, 349, 350t, 965t, 967
- Impetigo contagiosa, 25e-4f, 76e-8f, 829
- Impingement syndrome, 2248
- Implantable cardioverter-defibrillator (ICD)  
 CMR in patient with, 270e-9  
 complications of, 1499  
 endocarditis associated with. *See* Infective endocarditis, cardiovascular implantable device-associated  
 for heart failure, 1514, 1515t, 1770
- for hypertrophic cardiomyopathy, 1569–1570  
 indications for, 1499  
 for myocardial infarction, 1609, 1609f, 1770  
 travelers with, 799  
 for ventricular arrhythmias, 273e-7, 1495, 1499, 1499f  
 ventricular tachycardia and, 1491
- Implicit memory, 182
- Imprinting  
 definition of, 83e-7, 444e-2  
 disorders caused by, 430, 439  
 genomic, 430, 432f  
 penetrance and, 437
- Imprinting syndromes, 83e-7, 101e-4
- IMV (intermittent mandatory ventilation), 1741–1742, 1742t. *See also* Mechanical ventilation
- Incapacitating/behavior-altering agents, 262e-1t, 262e-2t
- Incidentalomas, adrenal, 2321, 2321t, 2322f
- Inclusion body myositis, **2194**  
 clinical features of, 462e-1, 2194–2196, 2195t  
 diagnosis of, 2199–2200, 2199t, 2201f  
 differential diagnosis of, 2197–2199  
 familial/hereditary, 2195–2196  
 immunopathology of, 2196, 2198f  
 nonimmune factors in, 2197  
 prognosis of, 2202  
 treatment of, 2200–2202  
 viral infections and, 2197
- Inclusion cyst, epidermoid, 342f, 364, 364t, 366
- Incompetent patient  
 advance directives for, 58  
 assessing capacity to make medical decisions, 17e-1  
 choice and role of surrogates, 17e-1–2  
 end-of-life care for, 66
- Incomplete penetrance, 437
- Incontinence  
 fecal. *See* Fecal incontinence  
 urinary. *See* Urinary incontinence
- Incontinentia pigmenti, 359, 360t, 431t
- Index of independence in activities of daily living, 78t
- India, 13e-7
- India ink, 150e-1
- Indian hedgehog, 2455
- Indian tick typhus, 1157
- Indigestion, **261**  
 approach to the patient, 262–263  
 definition of, 258  
 differential diagnosis of, 261–262, 1894  
 in esophageal disease, 1901  
 in GERD. *See* Gastroesophageal reflux disease (GERD)  
 mechanisms of, 261  
 treatment of, 263
- Indinavir  
 adverse effects of, 380, 1258, 1259, 2030  
 drug interactions of, 14e-4, 42t, 246e-3t  
 for HIV infection, 1278  
 metabolism of, 34t  
 molecular structure of, 1276f  
 resistance to, 1280f
- Indirect alloreactivity, 373e-5
- Indirect Coombs (indirect antiglobulin) test, 138e-4f
- Indirect fraction, 1995
- Indomethacin  
 for acute idiopathic pericarditis, 1573  
 for cough headache, 2597  
 drug interactions of, 43  
 for exertional headache, 2597  
 for gout, 2234  
 for hemicrania continua, 2596  
 for medullary thyroid cancer, 272  
 for nephrogenic diabetes insipidus, 2279  
 for pain, 91t  
 for paroxysmal hemicrania, 2596  
 for postprandial orthostatic hypotension, 2644  
 for reactive arthritis, 2175  
 for sex headache, 2597  
 for stabbing headache, 2598